Premium
[P3–001]: EFFECTIVENESS AND TOLERABILITY OF SOUVENAID IN CHINESE PATIENTS WITH MILD ALZHEIMER's DISEASE AND OTHER DEMENTIAS IN A REAL‐WORLD CLINIC SETTING: AN OPEN‐LABEL STUDY
Author(s) -
Chu Leung Wing
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1814
Subject(s) - tolerability , dementia , medicine , atrophy , memory clinic , vascular dementia , pediatrics , disease , adverse effect
Background:Neuronal health depends on the adequacy of multiple nutrients. Recently a treatment with multiple nutrients (Souvenaid) in mild AD has met some success. Souvenaid is a 125 ml (125-kcal) drink, which contains multiple nutrients including uridine monophosphate, phospholipid, choline, omega-3 fatty acids, vitamins and antioxidants. The latters are considered essential for the formation of synaptic membranes and synaptic functioning. The aim of this study was to investigate the effectiveness and tolerability of Souvenaid in Chinese patients with mild AD and other dementias in a real-world out-patient clinic setting. Methods: This was a 3-month open-label case series study, which was conducted in a single memory clinical centre from October 2014 to April 2016. The diagnosis of AD was in accordance with the 2011 NIA-AA criteria of probable AD dementia, with MRI brain imaging showing medial temporal atrophy and/or hippocampal atrophy. Results: 37 subjects completed their 3month follow-ups. At baseline, the mean (SD) age was 82.7 (8.5) years, and the mean MMSE score was 19.8. 67.6% of them were women. 91.9% (n1⁄434) of them had AD dementia, and 8.1% (n1⁄43) had vascular dementia (n1⁄42) or alcoholic dementia (n1⁄41). 86.5% of them were on approved symptomatic AD treatments. Souvenaid was well tolerated by 89.2% of the subjects. 10.8% had intolerance with minor GI side effects including diarrhoea, and abdominal cramps. Financially, 91.9% could afford the cost. Cognitively, the mean MMSE improved by 1.6 after 3 months (p1⁄40.006, paired t-test), and 60% of them showed improvements. Improvements in memory (caregivers’ reports), memory (self-reports), orientation to persons and place, activities of daily living (ADL) (caregivers’ report), ADL (self-reports), outdoor activities (self-reports), hobbies’ participation (caregivers’ reports) were observed in 46%, 43%, 43%, 27%, 30%, 27%, 32% and 33%, respectively. Improvements in behavioral psychological symptoms including apathy (caregivers’ reports), anxiety (caregivers’ reports), depression (self-reports), sleep (caregivers’ reports), and appetite (caregivers’ reports) were noted in 40%, 40%, 38%, 43%, and 38%, respectively. Conclusions:Adding Souvenaid to the existing symptomatic AD treatments is well tolerated, and it contributes to improvements in memory, and other cognitive functions, behaviour and daily activity among Chinese patients with mild AD or other dementias, over a 3 month period. P3-002 COGNITIVE EFFECTS OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN PATIENTS WITH SUBCORTICAL ISCHEMIC VASCULAR DEMENTIA: CASE EXPERIENCES Min Young Lee, Juyoun Lee, Hye Seon Jeong, Eungseok Oh, Eun Hee Sohn, Ae Young Lee, Chungnam National University Hospital, Daejeon, Republic of South Korea; Chungnam National University Hospital, Daejeon, Republic of South Korea. Contact e-mail: myapplecider@naver.com